Idogen Q4 2022: The future is contingent on funding - Redeye
Redeye leaves its comments on Idogen following its Q4 report. The company has paused its ongoing phase l/lla-trial and the financial position is stressed. We lower our fair value range accordingly.
ANNONS
Redeye leaves its comments on Idogen following its Q4 report. The company has paused its ongoing phase l/lla-trial and the financial position is stressed. We lower our fair value range accordingly.